H. Lundbeck A/S: Migraine Disorders trials

The registry lists 19 Migraine Disorders studies with H. Lundbeck A/S as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 4Phase 2 3Phase 3 9Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineRecruitingNCT05164172Phase 3
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheCompletedNCT05452239Phase 4Results posted
• Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedNCT05284019Phase 4Results posted
• A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsCompletedNCT05133323Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsCompletedNCT04418765Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of MigraineCompletedNCT04152083Phase 3Results posted
• An Open Label Trial of ALD403 (Eptinezumab) in Chronic MigraineCompletedNCT02985398Phase 3Results posted
• Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic MigraineCompletedNCT02974153Phase 3Results posted
• A Multicenter Assessment of ALD403 in Frequent Episodic MigraineCompletedNCT02559895Phase 3Results posted
• A Multicenter Assessment of ALD403 in Chronic MigraineCompletedNCT02275117Phase 2Results posted
• A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsCompletedNCT06701526Phase 4
• A Trial Investigating Lu AG09222 With Ubrogepant in Participants With MigraineCompletedNCT06578585Phase 1
• A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive TreatmentsCompletedNCT06323928Phase 2
• Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanCompletedNCT05064371Phase 3
• Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineCompletedNCT04921384Phase 3
• Eptinezumab in Adults With Migraine and Medication Overuse HeadacheCompletedNCT04772742Phase 3
• A Study in Children and Young People With Migraine to Learn What the Body Does to EptinezumabCompletedNCT04537429Phase 1
• Safety, Efficacy and Pharmacokinetics of ALD403CompletedNCT01772524Phase 1
• Safety Tolerability and Pharmacokinetics of ALD403CompletedNCT01579383Phase 1